About: Self-assembling Prodrug Nanotherapeutics for Synergistic Tumor Targeted Drug Delivery

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Self-assembling Prodrug Nanotherapeutics for Synergistic Tumor Targeted Drug Delivery Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Self-assembling Prodrug Nanotherapeutics for Synergistic Tumor Targeted Drug Delivery
Creator	Chen, Jiawei Little, Nicholas Lu, Jianqin Wang, Zhiren
Source	Elsevier; Medline; PMC
abstract	Abstract Self-assembling prodrugs represents a robust and effective nanotherapeutic approach for delivering poorly soluble anticancer drugs. With numerous intrinsic advantages, self-assembling prodrugs possess the maximum drug loading capacity, controlled drug release kinetics, prolonged blood circulation, and preferential tumor accumulation based on the enhanced permeability and retention (EPR) effect. These prodrug conjugates allow for efficient self-assembly into nanodrugs with the potential of encapsulating other therapeutic agents that have different molecular targets, enabling simultaneous temporal-spatial release of drugs for synergistic antitumor efficacy with reduced systemic side effects. The aim of this review is to summarize the recent progress of self-assembling prodrug cancer nanotherapeutics that are made through conjugating therapeutically active agents to Polyethylene glycol, Vitamin E, or drugs with different physicochemical properties via rational design, for synergistic tumor targeted drug delivery.
has issue date	2020-05-23(xsd:dateTime)
bibo:doi	10.1016/j.actbio.2020.05.026
bibo:pmid	32454086
has license	els-covid
sha1sum (hex)	f51b776ec07597a3003dc4d6b2c654a50f4990ba
schema:url	https://doi.org/10.1016/j.actbio.2020.05.026
resource representing a document's title	Self-assembling Prodrug Nanotherapeutics for Synergistic Tumor Targeted Drug Delivery
has PubMed Central identifier	PMC7245299
has PubMed identifier	32454086
schema:publication	Acta Biomater
resource representing a document's body	covid:f51b776ec07597a3003dc4d6b2c654a50f4990ba#body_text
is schema:about of	named entity 'delivering' named entity 'targeted drug delivery' named entity 'therapeutically' named entity 'tumor' named entity 'Tumor' named entity 'APPROACH' named entity 'SOLUBLE' named entity 'RETENTION' named entity 'POLYETHYLENE GLYCOL' named entity 'THESE' named entity 'TARGETS' named entity 'REDUCED' named entity 'ANTICANCER' named entity 'active' named entity 'therapeutic' named entity 'tumor' named entity 'controlled drug' named entity 'preferential' named entity 'loading' named entity 'synergistic' named entity 'kinetics' named entity 'effective' named entity 'soluble' named entity 'synergistic' named entity 'prodrug' named entity 'systemic side effects' named entity 'Polyethylene glycol' named entity 'self-assembling' named entity 'antitumor' named entity 'blood circulation' named entity 'Targeted Drug Delivery' named entity 'Synergistic' named entity 'Doxorubicin' named entity 'aromatic rings' named entity 'lactone' named entity 'UV absorbance' named entity 'antitumor' named entity 'hydrogen bonding' named entity 'physicochemical properties' named entity 'prodrugs' named entity 'solubility' named entity 'derivatization' named entity 'Chlorambucil' named entity 'FDA' named entity 'TRAF1' named entity 'selectively inhibiting' named entity 'self-assembly' named entity 'ester bond' named entity 'prodrug' named entity 'tumor growth' named entity 'self-assemble' named entity 'DLC' named entity 'lipophilic' named entity 'ethylene glycol' named entity 'solubility' named entity 'syngeneic' named entity 'adjuvant' named entity 'Taxol' named entity 'NIRF' named entity 'biodistribution' named entity 'red blood cells' named entity 'nanocarriers' named entity 'ester' named entity 'aqueous medium' named entity 'self-assemble' named entity 'MTD' named entity 'critical micelle concentration' named entity 'multidrug resistance' named entity 'conjugation' named entity 'Polymer' named entity 'anticancer activity' named entity 'cytotoxicity' named entity 'nanofibers' named entity 'polydispersity' named entity 'drug delivery systems' named entity 'Fmoc' named entity 'weakly acidic' named entity 'safety profile'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software